April 2, 2025
| Today’s news and insights for biopharma leaders
UPDATED
The Trump administration’s dramatic downsizing of the agency has put even closer attention on expected verdicts on drugs from Merck, Gilead and others.
|
The sweeping workforce reduction that began Tuesday was made worse by mistakes and poor communication, including directions for some CMS employees to contact a director who died last year.
|
Teams working on device communications and policy were cut from the agency on Tuesday, according to multiple FDA workers.
|
Accelerate biomarker research with high-quality, expert-curated data to drive precision medicine.
|
Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene and cell therapies.
|
News roundup
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of insolvency and Novartis hired a new top lawyer.
|
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
|
|
Recruiting and retaining participants is one of the biggest challenges faced by sponsors, CROs, and research sites in the clinical research field. Learn how to improve recruitment and retention in this infographic.
|
|
From Our Library
Playbook
Custom content for AgriNovus
|
Playbook
Custom content for Rentschler Biopharma
|
| 
